Intensity Therapeutics Inc

INTS03 Dec 2024
Healthcare
$2.91
-0.02 (-1.69%)
Lowest Today
$2.6
Highest Today
$2.95
Today’s Open
$2.91
Prev. Close
$2.93
52 Week High
$11.44
52 Week Low
$2.5
To Invest in Intensity Therapeutics Inc

Intensity Therapeutics Inc

Healthcare
INTS03 Dec 2024
-0.02 (-1.69%)
1M
3M
6M
1Y
5Y
Low
$2.6
Day’s Range
High
$2.95
2.6
52 Week Low
$2.5
52-Week Range
52 Week High
$11.44
2.5
1 Day
-
1 Week
-
1 month return
-15.43%
3 month return
-34.08%
6 month return
-43.19%
1 Year return
-5.05%
3 Years return
-
5 Years return
-
10 Years return
-
Institutional Holdings
Vanguard Group Inc
1.51
Vanguard Total Stock Mkt Idx Inv
1.21
Brown Advisory Holdings Inc
1.07
Geode Capital Management, LLC
0.46
Sigma Planning Corp
0.34
Mesirow Fin Investmt Mgmt Intl Equity
0.32
Vanguard Institutional Extnd Mkt Idx Tr
0.29

Market Status

Fundamentals
Market Cap
42.1 mln
PB Ratio
15.15
PE Ratio
0
Enterprise Value
39.47 mln
Total Assets
17.3 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Organisation
Intensity Therapeutics Inc
Employees
5
Industry
Biotechnology
CEO
Mr. Lewis H. Bender M.A., M.B.A., M.S.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities